Related Experiment Video
Updated: Aug 8, 2025
Protective Efficacy and Pulmonary Immune Response Following Subcutaneous and Intranasal BCG Administration in Mice
Published on: September 19, 2016
Effectiveness of the BNT162b2 vaccine in preventing COVID-19-associated deaths in Poland
Łukasz Pietrzak1, Kamil Polok2,3, Rafał Halik4
1Mazovian Pharmaceutical Chamber, Warsaw, Poland
Insights
The BNT162b2 vaccine demonstrated high effectiveness in preventing COVID-19 deaths in Poland. This vaccine significantly reduced mortality rates across all age groups studied.
Area of Science:
- Epidemiology
- Vaccinology
- Public Health
Background:
- The COVID-19 pandemic necessitated rapid vaccine development and deployment.
- The BNT162b2 vaccine (Pfizer-BioNTech) emerged as a key tool in mitigating the pandemic's impact.
Purpose of the Study:
- To evaluate the vaccination rates and real-world effectiveness of the BNT162b2 vaccine in Poland.
- To analyze vaccine effectiveness stratified by different age demographics.
Main Methods:
- Retrospective analysis of a large cohort of Polish citizens (over 36 million).
- Data sourced from national health registries and European surveillance centers.
- Comparison of mortality rates between fully vaccinated (BNT162b2) and unvaccinated individuals.
Main Results:
- The BNT162b2 vaccine showed an average effectiveness of 92.62% in preventing COVID-19-related deaths.
- Effectiveness ranged from 89.08% in individuals aged 80+ to 100% in those aged 5-17.
- Significantly lower mortality rates were observed in the vaccinated group across all age categories (43.76 vs 447.9 per 100,000).
Conclusions:
- The BNT162b2 vaccine is highly effective in preventing COVID-19 mortality in the Polish population.
- Vaccine effectiveness is consistently high across all age groups, underscoring its public health value.
Introduction:
Development of vaccines was a turning point of the COVID‑19 pandemic. In this study, we describe the course of the vaccination program in Poland and the effectiveness of the BNT162b2 vaccine.
Objectives:
The aim of the study was to analyze the vaccination rates and effectiveness stratified by age groups in Poland.
Patients And Methods:
This is a retrospective study based on the data on the vaccination rate and survival status among Polish citizens, obtained from the registries kept by the Polish Ministry of Health, the Statistics Poland, and the European Centre for Disease Prevention and Control. The data were collected between week 53 of 2020 and week 3 of 2022. The final analysis included patients who were either not vaccinated at all or fully vaccinated with the BNT162b2 vaccine.
Results:
The database contained records of 36 362 777 individuals, of whom 14 441 506 (39.71%) were fully vaccinated with the BNT162b2 vaccine and 14 220 548 (39.11%) were not vaccinated at all. The weekly average effectiveness of the BNT162b2 vaccine in preventing death was 92.62% and varied from 89.08% for the citizens aged 80 years and older, to 100% for individuals aged 5 to 17 years. The estimated mortality rate was significantly higher in the unvaccinated group than in the fully vaccinated group in the entire cohort (447.9 per 100 000 vs 43.76 per 100 000; P <0.001) in all age categories.
Conclusions:
The study results confirm high effectiveness of the BNT162b2 vaccine in preventing COVID‑19 deaths in all analyzed age groups.
Related Concept Videos
01:51Vaccinations
01:28Antimicrobial Effectiveness